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Abstract
Background: Fever is the clinical hallmark of malaria disease. The Roll Back Malaria (RBM) movement promotes prompt,
effective treatment of childhood fevers as a key component to achieving its optimistic mortality reduction goals by 2010. A
neglected concern is how communities will access these new medicines promptly and the costs to poor households when
they are located in rural areas distant to health services.
Methods: We assemble data developed between 2001 and 2002 in Kenya to describe treatment choices made by rural
households to treat a child's fever and the related costs to households. Using a cost-of-illness approach, we estimate the
expected cost of a childhood fever to Kenyan households in 2002. We develop two scenarios to explore how expected costs
to households would change if more children were treated at a health care facility with an effective antimalarial within 48
hours of fever onset.
Results: 30% of uncomplicated fevers were managed at home with modern medicines, 38% were taken to a health care facility
(HCF), and 32% were managed at home without the use of modern medicines. Direct household cash expenditures were
estimated at $0.44 per fever, while the total expected cost to households (cash and time) of an uncomplicated childhood fever
is estimated to be $1.91. An estimated mean of 1.42 days of caretaker time devoted to each fever accounts for the majority
of household costs of managing fevers. The aggregate cost to Kenyan households of managing uncomplicated childhood fevers
was at least $96 million in 2002, equivalent to 1.00% of the Kenyan GDP.
Fewer than 8% of all fevers were treated with an antimalarial drug within 24 hours of fever onset, while 17.5% were treated
within 48 hours at a HCF. To achieve an increase from 17.5% to 33% of fevers treated with an antimalarial drug within 48
hours at a HCF (Scenario 1), children already being taken to a HCF would need to be taken earlier. Under this scenario, direct
cash expenditures would not change, and total household costs would fall slightly to $1.86 because caretakers also save time
with prompt treatment if the child has malaria.
Conclusion:  The management of uncomplicated childhood fevers imposes substantial costs on Kenyan households.
Achieving substantial improvements in the numbers of fevers treated within 48 hours at a HCF with an effective antimalarial
drug (Scenario 1) will not impose additional costs on households. Achieving additional improvements in fevers treated
promptly at a HCF (Scenario 2) will impose additional costs on some households roughly equal to average cash expenses for
transportation to a HCF. Additional financing mechanisms that further reduce the costs of accessing care at a HCF and/or
that make artemisinin-based combination therapies (ACTs) accessible for home management need to be developed and
evaluated as a top priority.
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Background
Fever is the clinical hallmark of malaria disease. Diagnos-
tic reliance on fever alone, however, results in high diag-
nostic sensitivity but poor specificity [1,2]. Nevertheless,
as malaria is a common and frequently fatal disease
among young children in sub-Saharan Africa, fever is
regarded as a sufficient trigger for presumptive treatment
of children with antimalarial drugs in most malaria
endemic settings in Africa [3-5]. With more than 870 mil-
lion fever events among African children in 2000 [6], the
presumptive diagnosis of malaria in out-patient clinics
across the continent occurs in between 30–40% of all con-
sultations involving children [7].
The Roll Back Malaria (RBM) movement promotes
prompt, effective treatment of fevers as a key strategy for
achieving its optimistic mortality reduction goals [8].
RBM hopes to ensure that 80% of children receive effec-
tive antimalarial drugs within 24 hours of fever onset by
the year 2010 [9]. International attention has, rightly,
focused on the development [10], deployment [11,12],
and financing of effective medicines [13-15], particularly
artemisinin-based combination therapy (ACT). A separate
and less considered issue is how communities will access
these new medicines promptly and the costs to poor
households that are located in rural areas far from health
services.
Currently 32 countries in the World Health Organization
(WHO) Africa Regional Office have changed, or are in the
process of changing their first-line antimalarial drug pol-
icy to ACT [16]. Because very little pharmacovigilance
data or oversight is available in Africa [17], however, the
introduction of ACT has been cautious and confined
largely to prescription-only distribution in the formal sec-
tor. This approach to the introduction of ACT could
impose substantial additional costs on households if they
need to switch from widely practiced home-based man-
agement [18] to seeking treatment at a HCF to access the
new drugs.
In this paper, we assemble a series of data sets collected
between 2001 and 2002 through clinical, epidemiologi-
cal, and geographic studies on fever and malaria case-
management in Kenya to describe the sequences of treat-
ment choices made by rural households to treat a child's
fever and the related costs to households. These data are
used to estimate the expected cost of a childhood fever to
Kenyan households. We then develop two scenarios to
explore how household costs would change if a larger por-
tion of children were treated within 48 hours of fever
onset, given that artemether-lumefantrine (AL) is availa-
ble in the formal health sector only.
Methods
Definitions and approach
Regardless of their underlying causes, fevers in children
fall into three main categories: (1) uncomplicated fevers
treated at home and/or through outpatient services at a
health care facility (HCF) and clinically resolve; (2) com-
plicated febrile events that progress to life-threatening
conditions such as cerebral malaria and severe malaria
anemia, requiring hospital care that if effective will result
in cure; and (3) febrile events that lead rapidly to death
because of rapid pathological progression before reaching
tertiary care or failed treatment in tertiary care. The
malaria parasite and its human hosts have adapted to
ensure that uncomplicated fevers from malaria are
extremely common whilst severe disease and death from
malaria are comparatively rare [19]. Survey data used in
the present analysis show that 99.6% of fevers among
Kenyan children were either managed at home or as out-
patients, while only 0.4% were admitted to hospital [20].
Thus, we focus our analysis here on the costs to house-
holds of uncomplicated fevers from all causes in children
under five years.
We know that most fevers are not a direct consequence of
malaria infection. The presence of any infection in chil-
dren with fever presenting to clinics and retail outlets
across malaria endemic areas of Africa may range from 2–
64% depending on the intensity of malaria transmission
[1,21-26]. However, the potential for serious and fatal
outcomes developing rapidly from malaria if fevers in
young, semi-immune children are not treated presump-
tively for malaria outweighs the costs of improved diagno-
sis prior to treatment [4,5].
Since households in Africa typically have to manage ill-
nesses with fevers before knowing the primary cause, we
focus this analysis on the costs to households of managing
childhood fevers regardless of their cause. Using this
household perspective, we also explore how such costs
would change if these households followed international
recommendations that all fevers should be treated
promptly with an effective antimalarial in malaria
endemic areas such as our study districts. In Kenya, AL
began to be commonly available through government
and mission HCFs in September 2006 at no additional
cost to patients. Given this Kenyan policy, the primary
costs to households from prompt treatment at a HCF with
AL are changes in transportation costs and opportunity
costs of caretaker time. Understanding these household
costs is a prerequisite for designing appropriate mecha-
nisms and incentives that facilitate the prompt delivery of
febrile children to HCFs. Given our focus on costs to
households, we emphasize here that were do not address
related but separate topics, such as the costs to HCFs andBMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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the government of the adopted policy or the costs per ill-
ness event averted.
Throughout the paper, we use 'caretaker' to denote the
person primarily responsible for child health care deci-
sion making (e.g., the mother). In practice, however, we
realize that multiple caretakers may be involved in various
decisions or providing care to children in the household.
We start with the assumption that a household acts as a
joint decision making unit, adults are responsible for pri-
mary household decisions, and adults in the household
care about their children's health. In this case, a house-
hold's willingness to pay (WTP) to avoid a fever in a child
is conceptually a correct measure of the full cost of the
fever to the household. Harrington and Portney [27] show
that a household's WTP to avoid some unwanted health
event comprises three components: (1) the costs actually
borne by the household, including direct out-of-pocket
expenses from the illness plus the monetary value of the
time lost by household members (those ill and caretakers)
while taking care of their ill child; (2) the value of averting
expenditures made to avoid fevers in the first place; and
(3) the monetary value of the disutility (pain and suffer-
ing) to the household and child from the illness.
Since the cost of illness to households can be regarded as
a lower bound on the full cost to households as defined
by WTP, and since reasonably high-quality data exist on
the cost of illness, this paper follows a cost-of-illness
approach to estimate the expected cost of a childhood
fever to Kenyan households. And throughout this paper,
we use the word average to imply the expected value/
mean.
Data sources
We used primary data from three surveys all conducted in
late 2001 and early 2002 in four districts of Kenya: Greater
Kisii, Kwale, Bondo, and Makueni [20,28-30]. The four
districts are characteristic of the country's diverse malaria
epidemiology and socio-economic situation. In all four
districts, Kenyan national guidelines recommend pre-
sumptive treatment for malaria of all febrile children
below 5 years of age. First, a survey of 9,272 randomly
sampled homesteads between December 2001 and Janu-
ary 2002 collected detailed information on the manage-
ment strategies and costs of 2,655 pediatric fever episodes
experienced in the two weeks preceding the interview
[20]. As noted in the definitions sections, we emphasize
here that these are fevers from any cause, not fevers from
malaria alone, and cause of the fever is unknown. For this
analysis, we used data for the 1,565 uncomplicated fevers
that had resolved by the day of interview, as these repre-
sent fevers with a complete history of treatment actions.
We use these data to organize a model of home-based
fever management as practiced by households and associ-
ated costs of care. Second, to estimate travel times to vari-
ous service providers, we used data generated by non-
Euclidian distance models derived from 668 households
across the four districts [28]. And third, costs incurred by
households at a HCF were derived from interviews with
caretakers of 1,303 febrile children seen at 81 government
clinics in the four districts during the health facility sur-
veys undertaken at the same time as the community sur-
veys [30]. Costs at a HCF include any costs of treatment,
laboratory tests, and consultation fees incurred by the
caretakers.
Measuring the monetary value of caretaker time
Besides the actions taken by households to manage fevers,
information on direct cash expenses paid by households
during a fever and the monetary value or equivalent of
caretaker time devoted to the child during a fever are
needed for this analysis. Data on direct cash expenses paid
by households for travel and treatment (both at home and
at health care facilities) are directly available from the four
district surveys [20,28-30]. To compare and add up with
the same units, an estimate is needed of the monetary
value of caretaker time devoted to their child during a
fever.
The monetary value of caretaker time is a combination of
two factors: how much time caretakers allocate to uncom-
plicated fevers; and the monetary equivalent of the value
of caretaker's time. Regarding caretaker time, we could
find no information in published or unpublished litera-
ture that documents the fraction of time caretakers reallo-
cate from other activities to their children during an
uncomplicated fever or other forms of mild illnesses.
Given the focus here on uncomplicated fevers, we know
that caretakers are able to continue their normal daily
activities during much of the day when their child is
febrile. How much is unknown, and this issue remains a
good question for future research. As a starting point, or
base case assumption, we assume that caretakers allocate
an additional 0.25 days of their key productive time (2
hours per day assuming an 8 hour day) to their child dur-
ing a fever. Due to our uncertainty around this parameter,
we consider the implications of our analysis for higher
and lower values in the discussion.
Besides the quantity of caretaker time per child fever, we
also need an estimate of the monetary value of this time.
In a non-wage economy such as the rural Kenya setting of
this study, most income earning activities do not involve
direct wage payments or cash incomes, so that informa-
tion on the monetary value of caretaker time is difficult to
obtain. Data are not directly available in the primary data
discussed above for the four districts to estimate this
value.BMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
Page 4 of 12
(page number not for citation purposes)
As a result, we developed an estimate of the monetary
value of caretaker time based on a review of existing liter-
ature on poverty, adult daily income, and wages in Kenya.
As a starting point, the World Bank reports for 2002 that
national income was $11.1 billion, population was 31.3
million people, and per capita national income was $360
using the Atlas method for estimating income [31]. This
low level of per capita income, roughly $1 per day, reflects
well the country's rank (148th out of 177 countries) in the
human development index of the United Nations Devel-
opment Program [32].
Per capita income underestimates adult income because
children are included in the calculation. However, per
capita income overestimates average income because the
distribution of income in Kenya is very skewed: 20% of
the country's total population is estimated to earn 50% of
national income [33]. We therefore estimated a daily
income per adult based on national income for the bot-
tom 80% of the country ($5.55 billion for 25.04 million
people), which implies that per capita annual income for
the poorest 80% of the population is $221. Using the
average household size in the four study districts included
in our analysis of 8.91 people (see data sources discussion
above), average household income would be $1,975.
Finally, using the average of 5 adults in households, aver-
age daily income per adult can be estimated at $1.08.
Using survey data from 2001, Dolan and Sutherland [34]
report that the average daily wage for women horticultural
workers was $1.31 (assuming an 8 hour shift). Given that
there is substantial unemployment in Kenya and that a
large percentage of women work at least part of their time
in subsistence agriculture, this daily horticultural wage
over-estimates the mean value of women's time whether
in cash or non-cash production activities.
As another way of considering daily income, the Kenyan
poverty line was defined by the government as $0.50 per
day in 2002 [35], which overlaps the time period when
the primary data discussed in the next section was col-
lected. Precise information on the distribution of rural
income in Kenya is not available for 2002 or other recent
years. The World Bank does report that 53% of the rural
population was below the national poverty line in 1997
[32]. Again using the average household size of 8.91 and
5 adults per household from the primary data referenced
above, daily adult income would be $0.89 per day.
Based on the above discussion, we conclude that $1.00
per day provides a reasonable estimate of the average
monetary value of caretaker time in the four districts of
Kenya included in our study. Throughout the analysis, the
2002 annual average exchange rate of KES 78.30 per $1
US is used [36]. Because this analysis is developed for
uncomplicated fevers in children under five years, we
assume that the opportunity cost to the household of the
child's time is zero. While not directly comparable, we
note that $1 per day for adults was also used in a study of
malaria costs in Ethiopia [37].
Modeling average costs borne by households
Using the 1,565 fever events, we developed a simple deci-
sion tree to model the expected costs to households of a
childhood fever. Decision trees are commonly used when
estimating costs based on sequential decision making,
including cost-effectiveness analysis related to malaria
control [38,39]. While the decision tree approach used
here is entirely consistent with such literature, our focus
here is on the actions directly made by households related
to fever case management for their children.
The model outlined in Figure 1 is organized into three
management branches: treatment with modern medicines
at home, such as antipyretics, antibiotics and antimalar-
ials, where the fever resolves (Branch 1); delivery to a HCF
without prior treatment with modern medicines at home
(Branch 2); and management at home without modern
medicines and the fever resolves (Branch 3). As shown in
Figure 1, some percentage of fevers fall into each of the
three branches, where p1, p2, and p3 are used to denote the
proportion of fevers managed in each branch, with p1 +
p2+ p3 = 1.
Households incur costs of managing childhood fevers at
three stages. Stage 1 covers all household actions and costs
that occur at home, defined as the direct cash expenses for
medicines and possibly other treatment costs and the
value of caretaker time allocated to caring for the ill child.
Stage 2 includes decisions and costs associated with deliv-
ering a child to a HCF and returning home, defined as
cash expenses for transportation for the ill child and the
caretaker and the value of caretaker time at this stage.
Stage 3 covers all decisions and costs associated with
obtaining outpatient care at a health care facility, defined
as all fees paid by the caretaker for consultations, tests,
and medicines and the opportunity costs of caretaker time
while at a HCF and the additional time upon returning
home until the fever resolves.
For notation, let  ,  , and   represent expected costs
in Stage 1 (actions at home) for each branch, and Stage 1
ends when either the child recovers or is taken to a HCF.
Thus, the length of time associated with Stage 1 for each
branch can vary. For children taken to a HCF (Branch 2),
let   represent household costs for transportation and
the value of caretaker time lost in the round trip to the
facility, and let   represent costs at an HCF (Stage 3).
C1
1 C2
1 C3
1
C2
2
C2
3BMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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With the above notation, the expected value of costs to
households of an uncomplicated fever in a child can be
estimated as:
E(C) = p1  + p3  + p2 (  +   +  )   (1)
Actions taken at home (Stage 1) can involve 'looping'
within each branch or across branches [40,41]. For exam-
ple, a caretaker might manage a fever initially through rest
and comfort or herbal medicines (Branch 3). If the fever
does not resolve, additional rest and or traditional medi-
cines might be used (continuation of Branch 3), medi-
cines purchased in retail outlets might then be given to the
child (switch to Branch 1), or the child might be taken to
an HFC (switch to Branch 2). Rather than developing a
large series of management pathways to allow for all pos-
sibilities, the data available for each branch is consistent
with the final actions taken by a household for each stage.
So, for example, a child managed initially at home with-
out medicines (Branch 3) who then received an antima-
larial is considered to be in Branch 1 for this analysis.
We originally expected that some children treated at home
with modern medicines (Branch 1) would have later been
taken to a HCF, so that transportation and HCF costs for
children managed in Branch 1 would need to be included
in the decision tree. However, after a review of the data,
none of the children managed in Branch 1 were later
taken to a HCF. The decision tree outlined in Figure 1 can
be easily adapted to analyze such situations when empir-
ically relevant.
Results
Table 1 presents initial parameter values and calculations
used to estimate household costs of managing an uncom-
plicated fever event in children aged less than five years.
Except for two parameters, caretaker time per fever and the
monetary value of time, all parameters are means from the
primary data sources. As discussed above, we assume ini-
tially in Table 1 that $1 (KES 78.30) is the daily value of
caretaker time, and 0.25 days of caretaker time is allocated
to child care for each sick day.
Table 1 is organized according to the three stages and
three branches outlined in Figure 1. From the survey data
generated in 2001–2002, 30% of uncomplicated fevers
are managed at home with modern medicines (Branch 1),
38% are taken to a HCF (Branch 2), and 32% are managed
at home without the use of modern medicines (Branch 3).
Regarding costs at home in Stage 1 from Table 1, fevers
lasted on average for 4.8 days in Branch 1, 3.1 days in
C1
1 C3
1 C2
1 C2
2 C2
3
Household management of uncomplicated pediatric fevers in Kenya Figure 1
Household management of uncomplicated pediatric fevers in Kenya.
Child develops fever
Average costs at home 
C1
1
Probability (p1) treated at 
home with modern
medicines and fever 
resolved
“Branch 1”
“Branch 2”
“Branch 3”
Probability (p2) not treated 
at home with modern
medicines and taken 
to HCF 
Probability (p3) did
not receive modern
medicines at home 
and fever resolved
Average costs deliver to HCF
C2
2
Average amount paid
for outpatient treatment
C2
3
Average costs at home
C3
1
Average costs at home
C2
1
Stage 1 
(at home)
Stage 2 
(transport to HCF)
Stage 3 
(at HCF)BMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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Table 1: The average cost of a childhood fever in Kenya
Units Branch 1 Branch 2 Branch 3
Branch Probabilities probability ^1 0.30 0.38 0.32
Stage 1. Costs at Home
Child Days Sick This Stage Days ^1 4.80 3.10 4.60
Caretaker Time This Stage Days ^2 1.20 0.78 1.15
Value of Caretaker Time KES/Day ^2 78.30 78.30 78.30
Total Value of Caretaker Time This Stage KES 93.96 60.68 90.05
Cost Of Medicines and/or Other Treatments This Stage KES ^1 37.50 0.00 0.00
Total Cost Stage 1 KES 131.46 60.68 90.05
Stage 2. Cost of Travel to a HCF (Round Trip)
Caretaker Travel Time (Round Trip) Days ^3 0.50
Value of Caretaker Time KES/Day ^2 78.30
Total Value of Caretaker Time Stage KES 39.15
Cash Travel Expenses (Caregiver + Child) KES ^3 25.00
Total Cost Stage 2 KES 64.15
Stage 3. Costs at a HCF
% Treated with AM probability ^4 0.87
Average cost if treated with AM KES^4 35.70
% Not treated with AM probability^4 0.13
Average cost if not treated with AM KES^4 38.60
Average Cost at HCF KES 36.08
Caretaker Time at a HCF and at home until fever resolves Days ^2 0.68
Value of Caretaker Time KES/Day ^2 78.30
Total Costs Stage 3 KES 89.32
Mean cost of fever managed in each branch KES 131.46 214.15 90.05
$ 1.68 2.74 1.15
of which
direct cash expenditures KES 37.50 61.08 0.00
$ 0.48 0.78 0.00
days of caretaker time Days 1.20 1.96 1.15
opportunity cost of caretaker time KES 93.96 153.08 90.05
$ 1.20 1.96 1.15
Mean cost of fever KES 149.63
$ 1.91
Notes to Table:
^1 Amin et al. [20]
^2 Assumption discussed in text.
^3 Noor et al. [28]
^4 Zurovac et al. [30]BMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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Branch 2, and 4.6 days in Branch 3. It is likely that the
more serious fevers were managed in Branch 2 (taken to a
HCF) since they were taken to a HCF on average at least
1.5–1.7 days earlier than it took for fevers to resolve in
Branch 1 or Branch 3. Given the assumption that caretak-
ers lost 0.25 days of productive time for each day of fever,
we estimate in Stage 1 that caretakers allocated 1.20 days
on average per fever in Branch 1, 0.78 days in Branch 2,
and 1.15 days for Branch 3. For fevers managed in Branch
1, households spent on average KES 37.5 on average for
modern medicines. Households did not have cash expen-
ditures for managing fevers in Branch 3. In total, we esti-
mate that average costs at home (Stage 1) are KES 131.46
for Branch 1, KES 60.68 for Branch 2, and KES 90.05 for
Branch 3.
The same process is followed to estimate the average costs
in Stage 2 for children taken to a HCF (Branch 2). Data on
travel times to a HCF suggest a roundtrip travel time of 0.5
days, which also involves 0.5 days of caretaker time.
Besides travel time, households on average spent KES 25
on direct travel expenses. In total, average costs in Stage 2
are KES 64.15.
In Stage 3 based on costs at a HCF, 87% of children were
treated as outpatients with an antimalarial in 2002, and
on average caretakers paid KES 35.70 in fees at a HCF per
febrile child. Besides these direct cash expenses, the data
show that a typical visit to a HCF lasts for 1.5 hours (0.18
days), and we assume that a fever resolves on average in
two days after returning home (so 0.68 days of caretaker
time at this stage). In total for Stage 3, the value of care-
taker time and direct cash payments at a HCF are KES
89.32.
Across all three stages, household costs are estimated at
KES 131.46 ($1.68) for fevers managed at home with
modern medicines (Branch 1), KES 214.15 ($2.74) for
fevers managed as outpatients at a HCF (Branch 2), and
KES 90.05 ($1.15) for fevers managed at home without
modern medicines (Branch 3). Table 1 also reports in KES
and $US the main components of these costs (cash
expenses, caretaker time, and the value of caretaker time).
Using the branch probabilities reported in Table 1, the
mean cost of an uncomplicated childhood fever to Ken-
yan households is estimated at KES 149.63 in 2002, or
$1.91 at the average exchange rate for 2002.
Table 1 provides all parameters needed to estimate fever
costs as outlined in Figure 1 and equation 1. As discussed
above, the assumption that 0.25 days of caretaker time is
devoted to each fever is the only figure that is not based
on primary data sources or at least fairly solid secondary
sources (the $1 per day figure for the value of caretaker
time). Given the uncertainty around the amount of care-
taker time allocated per fever, Table 2 summarizes the
results of estimating the model with a higher and lower
figure for this parameter (0.5 and 0.125). While 0.5 days
per fever as a mean across all uncomplicated fevers is
probably too high, we suspect that 0.125 days is too low.
For each of these assumptions on caretaker time provided
in Table 2 under "Current Practice", direct cash expendi-
tures remain $0.44. Caretaker time ranges from 1.47 days
for the base case to 0.86 and 2.68 days for the lower and
higher range. Combining direct cash expenses and the
value of time, estimated fever costs are $1.30 for the lower
estimate, $1.91 for the base case, and $3.12 for the higher
estimate.
As shown in Table 2, the value of caretaker time accounts
for 77% of estimated costs for the base case (0.25 days of
caretaker time per fever day, and 1.47/1.91 = 0.77 or
77%), and 66% of estimated costs for the lower range
(0.125 days caretaker time per fever day). Total cash
expenses of $0.44 on medicines at home, transportation
to a HCF, and fees at a HCF (consultation, laboratory, and
drugs) are equal to 23% of costs in the base case (0.44/
1.91 = 0.23 or 23%) and 34% of costs for the lower range.
For perspective on the annual implications for house-
holds of childhood fevers, the most recent 2003 Kenya
Demographic and Health Survey reported that 40.6% of
children under five had a fever in the two weeks prior to
the interview [42]. Multiplying this two-week incidence
by 26, children in Kenya experience on average 10.5 fevers
annually. Thus, using the base case results of $1.91 per
fever from Table 1 and Table 2, the annual average cost to
households of fevers in one child is estimated to include
$4.62 in direct cash expenses and 15.44 days of caretaker
time, for a total of $20.06 annually. For the lower range of
0.125 days of caretaker time per fever day, cash expenses
remain at $4.62, caretaker time falls to 9.03 days, and
total annual average fever costs per child are $13.65.
ACT policy change scenarios
In Kenya one specific ACT, Artemether-lumefantrine (AL),
began to be available through government and mission
HCFs between July and September 2006 at no additional
costs to patients. Existing data suggest that Kenya is far
from achieving the "80% within 24 hours" target set by
RBM: our data show that fewer than 8% of fevers were
treated with an antimalarial within 24 hours of onset in
2001/2002. We emphasize here that this RBM target is
defined for all fevers in children under 5, not just fevers
from malaria. In practice this definition of within 24
hours is hard to define reliably through field investiga-
tion, and a more pragmatic target would be within 48
hours or same-day/next-day access to effective drugs.
Using this extended period as a yard-stick of theoreticalBMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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programme success, only 17.5% of fevers were treated
with an antimalarial within 48 hours at a HCF [20].
Here we investigate the implications for Kenyan house-
holds of achieving modest progress towards the RBM tar-
gets, from the current 17.5% to 33% and 50% of all fevers
receiving an antimalarial within 48 hours at a HCF, with
AL as the first-line recommended therapy. We provide two
scenarios for achieving this progress. For both scenarios
we assume that AL is introduced into the formal health
sector only, which is the Kenyan policy.
Scenario 1 – earlier delivery to a HCF for children already in Branch 2
As reported in Branch 2 of Table 1, current practice deliv-
ers 38% of fevers to a HCF, and fevers in this branch are
estimated to require 1.96 days of caretaker time. For these
children, only 53% were taken to a HCF within 48 hours
of fever onset, and only 87% of those taken actually
received an antimalarial drug (see Table 1, Stage 3 infor-
mation). In total, under current practice, 17.5% of all chil-
dren with fever are treated with an antimalarial at a HCF
(0.38*0.53*0.87 = 0.175)
To reach a target of 33% of all fevers treated with AL
within 48 hours when AL is only available at a HCF, which
is almost a 100% improvement on current practice, all the
children already being taken to a HCF (Branch 2) in Table
1 would need to depart home within 1.75 days of fever
onset, with an additional 0.25 days of transport time (2
hours), so that the child arrives at a HCF within 2 days.
The first implication of this scenario (Scenario 1) is that
caretaker time in Stage 1 for Branch 2 would fall from 0.78
days in Table 1 to 0.44 days.
For this scenario, cash expenses do not change because the
same people travel to a HCF. Costs at a HCF are also not
expected to change with the availability of AL because the
government has proposed to provide it free to all pediatric
patients.
While children in Branch 2 are delivered to a HCF on aver-
age 1.35 days earlier for Scenario 1 than current practice as
reported in Table 2, with a saving of 0.34 days of caretaker
time in Stage 1, earlier delivery to a HCF would only be
expected to reduce the overall illness time if the child has
malaria. For children delivered earlier in Branch 2 who do
not have malaria, receiving AL should have no impact on
the length of their fever. For these children, we would con-
tinue to expect on average that caretakers devote 1.96 days
of time to managing their child's fever (as in Table 1 for
Branch 2). In this case, earlier delivery to a HCF that saves
0.34 days of caretaker time in Stage 1 would simply imply
a longer fever resolution time (and 0.34 days of caretaker
time) in Stage 3 at home after a HCF visit.
Table 2: Fever costs by key components with alternative caretaker time assumptions
Base Case From Table 1. Lower Range Higher Range
0.25 days caretaker time 
per fever day
0.125 days caretaker time 
per fever day
0.5 days caretaker time per 
fever day
Current Practice: Units
direct cash expenditures $ 0.44 0.44 0.44
days of caretaker time Days 1.47 0.86 2.68
value of caretaker time $ 1.47 0.86 2.68
total (cash and time) $ 1.91 1.30 3.12
Scenario 1: 33% of fevers 
treated within 48 hours at 
a HCF with ACT
direct cash expenditures $ 0.44 0.44 0.44
days of caretaker time Days 1.42 0.84 2.58
value of caretaker time $ 1.42 0.84 2.58
total (cash and time) $ 1.86 1.28 3.02
Scenario 2: 50% of fevers 
treated within 48 hours at 
a HCF with ACT
direct cash expenditures $ 0.50 0.50 0.50
days of caretaker time Days 1.42 0.84 2.58
value of caretaker time $ 1.42 0.84 2.58
total (cash and time) $ 1.92 1.34 3.08BMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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Given the initial estimate of 0.68 days of caretaker time at
a HCF and at home after the visit for Branch 2 in Table 1,
we would now expect 0.68 + 0.34 = 1.02 days would be
the appropriate amount of caretaker time in Stage 3 for
children delivered to a HCF earlier without malaria. For
children taken earlier to a HCF earlier who have malaria,
earlier treatment should imply earlier resolution of the
fever. For these children, the estimate of 0.68 days of care-
taker time at a HCF and at home following remains the
correct figure. Assuming that only 40% of children with
fever in Branch 2 actually have malaria, on average
0.40*0.68 + 0.60*1.02 = 0.88 days of caretaker time is the
appropriate figure to include for caretaker time in Stage 3
for Scenario 1.
As reported in Table 2, reducing the time before delivery
to a HCF from 3.1 days to 1.75 days at home (Stage 1), but
not changing treatment seeking behavior of specific
households, reduces caretaker time on average per fever
across all three branches from 1.47 days for the base case
to 1.42 days for Scenario 1 (and from 1.96 days to 1.82
days for fevers in Branch 2). Given constant cash costs, the
average cost of a fever in Scenario 1 falls slightly to $1.86.
This scenario assumes that the availability of more effec-
tive medicines at HCFs would lead caretakers to change
their treatment seeking behavior to access treatment
within the 48-hour target. Whether this behavioral change
is possible depends on if community awareness cam-
paigns about AL are effective and word-of-mouth commu-
nity recognition of drug effectiveness affects behavior.
As shown in Table 2, the same qualitative results compar-
ing the base case with Scenario 1 hold whether 0.25,
0.125, or 0.5 days of caretaker time per fever day is used
for the analysis. Cash expenses do not change and some
caretakers save time. As a result, the overall average cost
per fever to households fall with earlier delivery to a HCF.
Scenario 2 – changing treatment seeking behavior
If we raised the numbers of children effectively managed
with AL within 48 hours from 33% of all fevers, as in Sce-
nario 1, to 50% (Scenario 2), treatment seeking behavior
would also need to change so that a larger percentage of
all fevers were taken to a HCF and prescribed AL. If the
percentage of fevers treated at home fell from 30% to
10.5%, for example, and instead these 19.5% of fevers
were delivered to a HCF within 48 hours, 57.5% of all
fevers would be managed in Branch 2 and 50% of all
fevers would be treated with AL at a HCF (assuming as in
Table 1 that 87% of fevers at a HCF are prescribed AL).
The first implication of Scenario 2 is that cash expenses
would increase by $0.30 for the 19.5% of all fevers
switched from Branch 1 to Branch 2. In Table 1, cash
expenses are $0.48 for fevers managed in Branch 1
because households purchased medicines used to manage
these fevers, while cash expenses are $0.78 for fevers man-
aged in Branch 2 because of transportation costs and fees
at a HCF. The difference between the two branches of
$0.30 is essentially equal to cash expenses for transporta-
tion in Branch 2.
In Scenario 2, the majority of children (38% of all fevers
out of the total 57.5% of all fevers in branch 2) are the
same children analyzed as part of Scenario 1 and, there-
fore, the numbers for their analysis do not change as part
of Scenario 2. Fevers for these children are estimated to
require 1.82 days of caretaker time on average (0.44 days
in Stage 1, 0.50 days in Stage 2, and 0.88 days in Stage 3).
The 19.5% out of 57.5% of all fevers now in Branch 2 for
Scenario 2 are children who were managed in Branch 1
(treated at home). As reported in Table 2, these fevers
resolved on average in 4.8 days, with an estimate of 1.20
days of caretaker time. Thus, fevers managed in Branch 1
resolved more quickly and required less caretaker time
(1.2 days of caretaker time) than fevers managed in
Branch 2 (1.82 days on average in Scenario 1). Delivery to
a HCF should not increase the overall time for these chil-
dren's fevers to resolve (fevers switched from Branch 1 to
Branch 2). Assuming that 0.44 days of caretaker time are
used in Stage 1 and 0.50 days for Stage 2, we would esti-
mate that 1.20 – 0.44 – 0.50 = 0.26 days is the maximum
average amount of caretaker time used in Stage 3 for the
fevers switched from Branch 1 to Branch 2. The 0.26 days
figure is a maximum because some of the fevers treated
earlier would be malaria, as discussed in Scenario 1, so
that their fever resolution time could fall with earlier AL
treatment. Thus, for all of the fevers managed in Branch 2
for Scenario 2, on average (0.195/0.575)0.26 + (0.38/
0.575)0.88 = 0.67 days of caretaker time would be used as
the overall average amount of caretaker time in Stage 3 of
Branch 2 for Scenario 2.
As shown in Table 2, the average cost of a fever across all
three branches is $1.92 for Scenario 2. Changing treat-
ment seeking behavior as considered in this scenario
would involve a $0.06 increase in direct cash expenses per
fever, and a slight decrease in days of caretaker time (0.05
days for the base case and the lower range). As discussed
above, however, all of the average cash cost increase
comes from a cash cost increase of $0.30 for the 19.5% of
fevers switched from Branch 1 to Branch 2.
Scenario 2 assumes that the majority of caretakers who
previously managed their children at home with modern
medicines (branch 1) would now instead bring their chil-
dren to a HCF. Again, whether this behavioral change is
possible depends on if community awareness campaignsBMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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are effective and word-of-mouth community recognition
of drug effectiveness affect behavior.
Discussion
We have estimated that the average cost of managing a
single uncomplicated pediatric fever to Kenyan house-
holds in 2002 was $1.91 based on a model of multiple
treatment pathways at different stages of a febrile event.
This estimate is based on primary data across four areas of
Kenya and the assumption that each fever day in a child
requires 0.25 days on average of caretaker time. If only
0.125 days of caretaker time are required on average per
fever day, average costs remain $1.30. Annually, the cost
to households of fevers in one child for both the 0.25 and
0.125 assumption are estimated at $20.06 and $13.65,
which includes cash expenses of $4.62 for both and 15.44
and 9.03 days caretaker time respectively.
As would be expected, there are a range of costs around
this average. Some fevers are managed at home without
additional medicines, last for a short time, involve little or
no additional adult caretaker time, and as a result entail
almost zero cost. On the other hand, if a child remains at
home for several days and is then taken to a facility, the
cost of such a fever could be in excess of $4.00, with the
opportunity cost of caretaker time still accounting for the
vast majority of the total.
The most recent 2003 Kenya Demographic and Health
Survey of 10,000 households in 400 clusters located
across Kenya's eight provinces reported that 40.6% of chil-
dren under five had a fever in the two weeks prior to the
interview, with a low of 23.2% in North Eastern Province
and a high of 59.8% in Western Province [42]. Projecting
Kenya's provincial population data from the last national
census in 1999 through to 2005, using the provincial fever
prevalence estimates from the 2003 KDHS, and assuming
a lower annual incidence as 26 times the two week period
prevalence estimate [6], we estimate that there were 55.53
million childhood fevers in 2005 and conservatively esti-
mate that 50 million of these would be uncomplicated.
Assuming that the number of fevers in 2002 was essen-
tially the same as 2005, and using the $1.92 cost per fever
from Table 1, the aggregate cost to Kenyan households of
managing uncomplicated childhood fevers was $96 mil-
lion in 2002, representing a direct cost to the Kenyan
economy equivalent to 1.00% of annual Kenyan gross
2002 national income.
Our data and modeled estimates of cost presented in
Table 1 and Table 2 under Current Practice represent a sit-
uation that prevailed before the introduction of ACTs in
Kenya. During the era of failing drugs, only 17.5% of
fevers were managed at a HCF within 48 hours, presenting
a double challenge for effective malaria case-management
in febrile children: ineffective drugs and poor access. The
new drug policy was implemented in 2006 and is limited
to the formal health sector.
We have examined two approaches for increasing effective
coverage of new medicines when these are limited to the
formal health sector. The first approach, Scenario 1, is to
reduce the time between fever onset and delivery to a HCF
to 48 hours for the 38% of fevers already being taken to a
HCF. As shown in Table 2, achieving this change in behav-
ior would increase the percentage of children receiving an
effective antimalarial from 17.5% to 33%, cash expenses
would not change, and the average cost of a fever would
fall slightly to $1.86, with all of the cost savings from
reducing the value of caretaker time.
The second, complementary approach (Scenario 2) would
be to seek further behavioral change where more caretak-
ers manage the febrile child at a HCF rather than manage
at home with retail sector drugs. While the average cost
across all fevers in Scenario 2 remains essentially the same
as estimated as current practice, Scenario 2 does involve a
shift from cash expenses at home for medicines to cash
expenses for transportation and fees at a HCF, with a net
increase of $0.30 per fever for the 19.5% of fevers
switched from home management to care at a HCF.
With the RBM goal of prompt treatment of 80% of all
childhood fevers at a HCF by 2010, the analysis presented
here for Scenario 1 shows that Kenyan can achieve sub-
stantial progress towards this target by focusing on earlier
delivery of children already being taken to a HCF. In other
words, the first 41% (33% out of 80%) of the RBM target
can be achieved without imposing additional costs on
households. To achieve further progress, Scenario 2 shows
that 63% of the RBM target (50% of all fevers out of 80%)
could be achieved in Kenya with an estimated $0.30
increase in cash expenses for 19.5% of all fevers.
While making new medicines more accessible over-the-
counter (OTC) in the retail sector could save caretakers
travel time and expenses for fever management [26,43],
unsubsidized retail prices of KES 300 or more for a child
ACT course are prohibitive for poorer households. If the
situation described for 2001/2002 prevails in 2009, when
AL is anticipated to be deregulated for OTC use in Kenya,
but the cost of drugs is not centrally subsidized, the aver-
age costs to households would increase substantially if
retails purchases of ACT increased substantially. We
doubt, however, that caretakers formerly managing fevers
at home with inexpensive retail medicines would switch
and actually purchase new medicines at unsubsidized
prices. In the absence of highly subsidized prices at the
retail level, increasing this percentage through OTC access
is highly unlikely.BMC Public Health 2006, 6:314 http://www.biomedcentral.com/1471-2458/6/314
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Conclusion
These analyses highlight several implications of changing
malaria treatment policy in Kenya. First, limiting new
drugs to a single sector and aiming to increase prompt
access will not increase opportunity costs to impoverished
households who are already taking their children to a HCF
(Scenario 1). On average, prompt access will shorten time
managing a fever at home for fevers associated with
malaria. Second, the only option to increase prompt
access when new drugs are limited to a single sector is to
encourage people to travel earlier to service providers, rep-
resenting investment in major behavioral change initia-
tives at community levels. Such initiatives need to
differentiate messages to target, for example, households
who tend to take their children to a HCF but later than rec-
ommended (e.g., after two days), households who tend to
manage fevers at home but could access a HCF if required
for little or no cash expense, and households who manage
fevers at home but can only access a HCF with significant
cash expenses. And third, unless new drugs are heavily
subsidized in the retail sector, achieving more than 50%
of all fevers treated promptly at a HCF (63% of the RBM
target of 80%) would increase substantially the average
costs to households of managing pediatric fevers in
Kenya. For Kenya to achieve substantial increases beyond
Scenario 2, the international community and Kenyan gov-
ernment must find financing options that make the cost
of accessing new ACT drugs more affordable to poor rural
households [14].
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